Early diagnostic markers of diabetes associated pancreatic cancer

2020 Fiscal Year Final Research Report

• Project/Area Number: 19K17431
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 53010:Gastroenterology-related
• Research Institution: Osaka University
• Principal Investigator: Sato Katsuhiko 大阪大学, 医学部附属病院, 医員 (40838843)
• Project Period (FY): 2019-04-01 – 2021-03-31
• Keywords: 膵癌 / 糖尿病

Outline of Final Research Achievements

Diabetes mellitus is a known risk of pancreatic cancer. Our study focused on the point that hyperglycemia enhanced neuroendocrine character in pancreatic cancer cells. We aimed to clarify the mechanism of diabetes-related pancreatic cancer and finding an early diagnostic marker. We used multiple pancreatic cancer mouse models and induced hyperglycemia. In genetically engineered pancreatic cancer mouse model, we could not show that hyperglycemia enhances pancreatic cancer progression. However, we showed that high glucose preconditioned pancreatic cancer cells make larger tumors when orthotopically injected to pancreatic tail. This phenomenon was seen in immunodeficient mouse model with human pancreatic cancer cell lines, and in immunocompetent mouse model with mouse derived pancreatic cancer cell lines.

Free Research Field

膵癌

Academic Significance and Societal Importance of the Research Achievements

我々の研究は糖尿病と膵癌の関連性に注目し、糖尿病併存膵癌の進展機序および早期診断マーカーを同定することを目的とした。進行膵癌を形成する膵発癌モデルマウスでは高血糖が膵発癌を促進するかは明らかにできなかった。高グルコースで培養した膵癌細胞株は低グルコースで培養した膵癌細胞株と比べて、より大きな腫瘍を形成することが確認された。糖尿病の中の高血糖という一側面が膵発癌を促進することを我々は確認し、学会および論文に発表している。糖尿病と膵癌は非常に関連が深く、今後の検討が望まれる。